CVI Holdings LLC acquired a new stake in shares of Heat Biologics Inc (NASDAQ:HTBX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,557,768 shares of the biopharmaceutical company’s stock, valued at approximately $1,527,000. Heat Biologics accounts for about 3.4% of CVI Holdings LLC’s portfolio, making the stock its 6th largest holding. CVI Holdings LLC owned about 0.07% of Heat Biologics as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Northern Trust Corp bought a new stake in shares of Heat Biologics during the 2nd quarter valued at $111,000. Virtu Financial LLC bought a new stake in shares of Heat Biologics during the 4th quarter valued at $55,000. Vanguard Group Inc grew its position in shares of Heat Biologics by 20.6% during the 3rd quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after acquiring an additional 136,256 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Heat Biologics by 20.6% during the 3rd quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after acquiring an additional 136,256 shares during the period. 16.39% of the stock is owned by hedge funds and other institutional investors.

Separately, ValuEngine downgraded shares of Heat Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 25th.

Shares of Heat Biologics stock opened at $1.24 on Friday. Heat Biologics Inc has a fifty-two week low of $0.95 and a fifty-two week high of $4.30.

TRADEMARK VIOLATION WARNING: This story was first posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.mareainformativa.com/news/2019/03/17/1557768-shares-in-heat-biologics-inc-htbx-purchased-by-cvi-holdings-llc.html.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Recommended Story: Why is cost of goods sold important?

Want to see what other hedge funds are holding HTBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heat Biologics Inc (NASDAQ:HTBX).

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.